Merck KGaA outlicenses monoclonal antibody to Cancer Research UK programme
This article was originally published in Scrip
Executive Summary
Cancer Research UK and its development and commercialisation arm Cancer Research Technology (CRT) are to conduct a Phase I trial of Merck KGaA's monoclonal antibody DI-B4 as part of its Clinical Development Partnerships (CDP) programme.